

A. Originalarbeiten (peer review)

1. Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease.
Spichtig D, Zhang H, Mohebbi N, Pavik I, Petzold K, Stange G, Saleh L, Edenhofer I, Segerer S, Biber J, Jaeger P, **Serra AL**, Wagner CA.
Kidney Int. 2014 Jan 8.
IF 7.916
2. The role of phospholipase D in modulating the MTOR signaling pathway in polycystic kidney disease.
Liu Y, Käch A, Ziegler U, Ong AC, Wallace DP, Arcaro A, **Serra AL**.
PLoS One. 2013 Aug 23;8(8):e73173.
IF 3.730
3. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
Pavik I, Jaeger P, Ebner L, Wagner CA, Petzold K, Spichtig D, Poster D, Wüthrich RP, Russmann S, **Serra AL**.
Nephrol Dial Transplant. 2013 Feb;28(2):352-9.
IF 3.371
4. Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study.
Kistler AD, **Serra AL**, Siwy J, Poster D, Krauer F, Torres VE, Mrug M, Grantham JJ, Bae KT, Bost JE, Mullen W, Wüthrich RP, Mischak H, Chapman AB.
PLoS One. 2013;8(1):e53016.
IF 3.730
5. Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation.
Ho TA, Godefroid N, Gruzon D, Haymann JP, Maréchal C, Wang X, **Serra A**, Pirson Y, Devuyst O.
Kidney Int. 2012 Nov;82(10):1121-9.
IF 7.916
6. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice.
Terry W, Cochat P, Froissart R, Ortiz A, Pirson Y, Poppe B, **Serra A**, V Biesen W, Vanholder R, Wanner C.
Nephrol Dial Transplant. 2013;28(3):505-17.
IF 3.371
7. Targeting of sodium-glucose co-transporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD Rats.
Xueqi Wang X, Suhua Zhang S, Liu Y, Spichtig D, Kapoor S, Koepsell H, Mohebbi N, Segerer St, **Serra AL**, Rodriguez D, Devuyst O, Mei C, Wüthrich RP.
Kidney Int. 2013 Nov;84(5):962-8.
IF 7.916
8. Ovarian Toxicity from Sirolimus.
Braun M, Young J, Reiner C, Poster D, Wüthrich RP, **Serra AL**.
N Engl J Med. 2012;366(11):1062-4.
IF 51.658
9. TUMORAPA Study Group. Sirolimus and secondary skin-cancer prevention in kidney transplantation. Euvrard S, Morelon, Lionel Rostaing, Eric Goffin E, Brocard, Tromme I, Broeders I, del Marmol V, Chatelet V, Dompmartin A, Kessler M, **Serra AL**, Hofbauer G, Pouteil-Noble C, Campistol J, Kanitakis J, Roux A, Decullier E, Dantal J.
N Engl J Med 2012; 367:329-339.
IF 51.658

10. Low-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISSE ADPKD trial.
Braun M, Young J, Reiner CS, Poster D, Krauer F, Kistler AD, Kristanto P, Wang X, Liu Y, Loffing J, Andreisek G, von Eckardstein A, Senn O, Wüthrich RP, **Serra AL**.
PLoS One. 2012;7(10):e45868.

IF 3.730

11. Reversal of UVA Skin Photosensitivity and DNA Damage in Kidney Transplant Recipients by Replacing Azathioprine.
Hofbauer GF, Attard NR, Harwood CA, McGregor JM, Dziunycz P, Iotzova-Weiss G, Straub G, Meyer R, Kamenisch Y, Berneburg M, French LE, Wüthrich RP, Karran P, **Serra AL**.
Am J Transplant. 2012 Jan;12(1):218-25.

IF 6.192

12. Growth of Arachnoid Cysts in Patients with Autosomal Dominant Polycystic Kidney Disease: Serial Imaging and Clinical Relevance.
Krauer F, Ahmadli U, Kollias S, Bleisch J, Wüthrich RP, **Serra AL**, Poster D.
CKJ 2012.

IF 0.230

13. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study. Pavik I, Jaeger P, Ebner L, Wagner CA, Petzold K, Spichtig D, Poster D, Wüthrich RP, Russmann S, **Serra AL**.
Nephrol Dial Transplant. 2012.

IF 3.371

14. Sirolimus induced phosphaturia is not caused by inhibition of renal apical sodium phosphate cotransporters.
Haller M, Amatschek S, Wilflingseder J, Kainz A, Bielesz B, Pavik I, **Serra A**, Mohebbi N, Biber J, Wagner CA, Oberbauer R.
PLoS One. 2012.

IF 3.730

15. Quantitative BOLD response of the renal medulla to hyperoxic challenge at 1.5T and 3.0T.
Donati OF, Nanz D, **Serra AL**, Boss A.
NMR Biomed. 2012 Jan 31. doi: 10.1002.

IF 3.446

16. Soluble Klotho and Autosomal Dominant Polycystic Kidney Disease. Pavik I, Jaeger P, Ebner L, Poster D, Krauer F, Kistler AD, Rentsch K, Andreisek G, Wagner CA, Devuyst O, Wüthrich RP, Schmid C, **Serra AL**.
Clin J Am Soc Nephrol. 2012; (2):248-57.

IF 5.068

17. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.
Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, **Serra AL**, Maródi L, Mignani R, Vujkovic B, Beitner-Johnson D, Lemay R, Cole JA, Svarstad E, Waldek S, Germain DP, Wanner C; on behalf of the Fabry Registry.
Nephrol Dial Transplant. 2012 Mar;27(3):1042-9.

IF 3.371

18. Urinary proteomic biomarkers enable diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multi-centric study.
Kistler AD, **Serra AL**, Siwy J, Poster D, Krauer F., Torres VE, Mrug M, Grantham JJ, Bae KT, Bost JE, Mullen W, Wüthrich RP, Mischak H, Chapman AB.
PLoS One. 2012.

IF 3.730

19. Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation. Ho TA, Godefroid N, Gruzon D, Haymann JP, Maréchal C, Wang X, **Serra A**, Pirson Y, Devuyst O.
Kidney Int. 2012 Nov;82(10):1121-9.

IF 7.916

20. A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy.
Kistler AD, Siwy J, Breunig F, Jeevaratnam P, Scherl A, Mullen W, Warnock DG, Wanner C, Hughes DA, Mischak H, Wüthrich RP, **Serra AL**.
PLoS One. 2011;6(6):e20534.

IF 3.730

21. Skin cancer development in solid organ transplant recipients: a 2 year interim analysis of the Swiss Transplant Cohort Study (STCS).
Staubli M, Anliker M, Arnold A, Hunger R, Kempf W, Laffitte E, Lapointe AK, Mainetti C, Pelloni F, Streit M, Fehr T, **Serra A**, Hofbauer GF.
J of Investigative Dermatology, 2011; (131): S25-S25.

IF 6.193

22. Anti-VEGF treatment accelerates polycystic kidney disease.
Raina S, Honer M, Krämer SD, Liu Y, Wang X, Segerer S, Wüthrich RP, **Serra AL**.
Am J Physiol Renal Physiol. 2011 Oct;301(4):F773-83.

IF 3.612

23. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangiomyomatosis: a phase 2 trial.
Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, **Serra AL**, Watson PC, Howe CJ, Doyle T, Pointon K, Cross JJ, Tattersfield AE, Kingswood JC, Sampson JR.
Clin Cancer Res. 2011 Jun 15;17(12):4071-81.

IF 7.837

24. Renal Function in Patients Treated with Cinacalcet for Persistent Hyperparathyroidism after Kidney Transplantation.
Henschkowski J, Bischoff-Ferrari HA, Wüthrich RP, **Serra AL**
Kidney Blood Press Res. 2011; 34:97-103.

IF 1.596

25. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate.
Pavik I, Jaeger Ph., Kistler AD., Poster D., Krauer F, Cavelti-Weder C, Rentsch K, Wüthrich RP and **Serra AL**.
Kidney Int. 2011;79(2):234-40.

IF 7.916

26. Azathioprine withdrawal results in reduction in UVA photosensitivity but persistence of potentially mutagenic DNA thiopurines.
Attard NR, Hofbauer G, Straub G, **Serra A**, Harwood CA, McGregor J, Karran P.
Br J of Dermatology, 2010;162:920.

IF 3.759

27. Prognostic Indicators of Renal Disease Progression in Adults with Fabry Disease: Natural History Data from the Fabry Registry.
Wanner C, Oliveira, JP, Ortiz A, Mauer M, Germain DP, Linthorst G, **Serra AL**, Maródi L, Mignani R, Cianciaruso B, Vujkovic B, Lemay R, Beitner-Johnson D, Waldek S and Warnock DG.
Clin J Am Soc Nephrol. 2010;5(12):2220-8.

IF 5.068

28. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wüthrich RP.
N Engl J Med. 2010 Aug 26;363(9):820-9.

IF 51.658

29. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease.
Wu M, Arcaro A, Varga Z, Vogetseder A, Le Hir M, Wüthrich RP, **Serra AL**. Am J Physiol Renal Physiol.
Am J Physiol Renal Physiol. 2009 Dec;297(6):F1597-605.

IF 3.612

30. Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease.
Serra AL, Kistler AD, Poster D, Krauer F, Senn O, Raina S, Pavik I, Rentsch K, Regeniter A, Weishaupt D, Wüthrich RP.
Nephrol Dial Transplant. 2009 Nov;24(11):3334-42.

IF 3.371

31. Kidney function and volume progression in unilateral ADPKD with contralateral renal agenesis or hypoplasia: a case series.
Poster D, Kistler AD, Krauer F, Blumenfeld JD, Rennert H, Weishaupt D, Wüthrich RP and **Serra AL**.
Am J Kidney Dis. 2009 Sep;54(3):450-8.

IF 5.294

32. Identification of a unique urinary biomarker profile in autosomal dominant polycystic kidney disease.
Kistler AD, Mischak H, Poster D, Dakna M, Wüthrich RP and **Serra AL**.
Kidney Int. 2009 Jul;76(1):89-96.

IF 7.916

33. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients.
Grimmelt A, Cohen CD, Fehr T, **Serra AL** and Wüthrich RP.
Clin Nephrol. 2009;71(2):125-9.

IF 1.288

34. Increases in kidney volume in Autosomal Dominant Polycystic Kidney Disease can be detected within 6 months.
Kistler AD, Poster D, Krauer F, Weishaupt D, Raina S, Senn O, Binet I, Spanaus K, Wüthrich RP and **Serra AL**.
Kidney Int. 2009 Jan;75(2):235-41.

IF 7.916

35. Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism.
Serra AL, Wuhrmann C, Wüthrich RP.
Am J Kidney Dis. 2008 52(6):1151-7.

IF 5.294

36. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a tuberous sclerosis patient.
Hofbauer GFL, Marcollo-Pini A, Corsenca A, Kistler AD, French LE, Wüthrich RP, **Serra AL**.
Br J Dermatol. 2008 Aug;159(2):473-5.

IF 3.759

37. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation.
Serra AL, SC Braun, A Starke, R Savoca, M Hersberger, S Russmann, N Corti and RP Wüthrich.
Am J Transplant. 2008 Apr;8(4):803-10.

IF 6.192

38. Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of ADPKD.
Berthier CC, Wahl PR, Le Hir M, Marti HP, Wagner U, Rehrauer H, Wüthrich RP, **Serra AL**.
Nephrol Dial Transplant. 2008 Mar;23(3):880-9.

IF 3.371

39. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSSE ADPKD study.
Serra AL, Kistler A, Poster D, Strucker M, Wüthrich RP, Weishaupt D, Tschirch F. [NCT00346918].
BMC Nephrology 2007 Sep 15;8(1):13.

IF 1.644

40. Mitotic activation of Akt signalling pathway in Han:SPRD rats with polycystic kidney disease.
Wahl PR, Le Hir M, Vogetseder A, Arcaro A, Starke A, Waeckerle-Men Y, **Serra AL**, Wüthrich RP.
Nephrology. 2007 Aug;12(4):357-63.

IF 1.688

41. Six-year follow up of azathioprine and mycophenolate mofetil use during the first 6 months of renal transplantation.
Rippin S, **Serra AL**, Marti HP and Wüthrich RP.
Clin Nephrol. 2007 Jun;67(6):374-80.

IF 1.288

42. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients.
Serra AL, Savoca R, Huber AR, Hepp U, Delsignore A, Hersberger M, Wüthrich RP.
Nephrol Dial Transplant. 2007 Feb;22(2):577-83.

IF 3.371

43. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease.
Wu M, Wahl PR, Le Hir M, Wackerle-Men Y, Wuthrich RP, **Serra AL**.
Kidney Blood Press Res. 2007 Jun 27;30(4):253-259.

IF 1.596

44. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
Wahl PR, **Serra AL**, Le Hir M, Molle KD, Hall MN, Wüthrich RP.
Nephrol Dial Transplant. 2006 Mar;21(3):598-604.

IF 3.371

45. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism.
Serra AL, Schwarz AA, Wick FH, Marti HP, Wüthrich RP.
Nephrol Dial Transplant. 2005 Jul;20(7):1315-9.

IF 3.371

46. Sodium retention in rats with liver cirrhosis is associated with increased renal abundance of NaCl cotransporter (NCC).
Yu Z[†]; **Serra A**[†]; Sauter D; Loffing J; Ackermann D; Frey F, Frey B; Vogt B.
Nephrol Dial Transplant. 2005 Sep;20(9):1833-41.

IF 3.371

47. Hypoxia causes down-regulation of 11 beta-hydroxysteroid dehydrogenase type 2 by induction of Egr-1.
Heiniger CD, Kostadinova RM, Rochat MK, **Serra A**, Ferrari P, Dick B, Frey BM, Frey FJ.
FASEB J. 2003 May;17(8):917-9.

IF 5.704

48. Glycyrrhetic acid decreases plasma potassium concentrations in patients with anuria.
Serra A, Uehlinger DE, Ferrari P, Dick B, Frey BM, Frey FJ, Vogt B.
J Am Soc Nephrol. 2002 Jan;13(1):191-6.

IF 8.987

49. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful.
Vogt B, Ferrari P, Schonholzer C, Marti HP, Mohaupt M, Wiederkehr M, Cereghetti C, **Serra A**, Huynh-Do U, Uehlinger D, Frey FJ.
Am J Med. 2001 Dec 15;111(9):692-8.

IF 4.768

50. Efficiency of airway macrophage recovery by bronchoalveolar lavage in hamsters: a stereological approach.
Geiser M, **Serra AL**, Cruz-Orive LM, Baumann M, Im Hof V, Gehr P.
Eur Respir J. 1995 Oct;8(10):1712-8.

IF 6.355

Fallbeschreibungen (case reports)

1. Hydronephrosis in autosomal dominant polycystic kidney disease.
Kistler AD, Poster D, Wüthrich RP, **Serra AL**
Kidney Int. 2009 Dec;76(12):1297.
IF 7.916

2. Maltese cross-like crystals in the urinary sediment of a diabetic patient.
Etter Ch, Russi R, Fogazzi GB, Wüthrich RP, **Serra AL**.
NDT Plus 2009; 2:405-407
IF 0.000
3. Combined nephrectomy and preemptive renal transplantation in a patient with tuberous sclerosis complex.
Corsenca A, Moch, M, Weber M, Wüthrich RP, **Serra AL**.
Nephrol Dial Transplant. 2007 22(11):3330-3.
IF 3.371
4. A puzzling case of high serum creatinine in a healthy woman.
Serra AL, Klein M, Nitsch D, Durr D, Wermuth B, Frey FJ.
Nephrol Dial Transplant. 2006 5:1456-7.
IF 3.371

B. Übersichtsarbeiten (Reviews)

1. Looking at the (w)hole: magnet resonance imaging in polycystic kidney disease.
Liebau MC, **Serra AL**.
Pediatr Nephrol. 2013 Sep;28(9):1771-83.
IF 2.939
2. The educational website Dermaguard to prevent the incidence of skin care after transplantation.
Bühler MN, Feldmeyer L, Wüthrich RP, French LE, Djamei V, **Serra AL**, Hofbauer GF.
Praxis (Bern 1994). 2013 Nov 13;102(23):1415-20.
IF 0.059
3. Assessment of proteinuria.
Nowak A, **Serra AL**.
Praxis (Bern 1994). 2013 Jun 19;102(13):797-802.
IF 0.059
4. Pre- and posttransplant management of solid organ transplant recipients: risk-adjusted follow-up.
Schreve BS, Anliker M, Arnold AW, Kempf W, Laffitte E, Lapointe AK, Mainetti C, Pelloni F, Oberholzer P, Serra AL, Streit M, Hofbauer GF; working group Organ Transplantation, Swiss Society for Dermatology and Venerology.
Curr Probl Dermatol. 2012;43:57-70.
IF 0.334
5. Maligne Hauterkrankungen bei organtransplantierten Patienten.
Göksu Y, Hofbauer G, Serra A, Nowak A.
Praxis (Bern). 2012
IF 0.059
6. Vasopressin-2 receptor antagonists in autosomal dominant polycystic kidney disease: from man to mouse and back.
Devuyst O, Wang X, **Serra A**.
Nephrol Dial Transplant. 2011 Aug;26(8):2423-5.
IF 3.371
7. Swiss clinical practice guidelines for skin cancer in organ transplant recipients.
Lapointe AK, Hofbauer G, Anliker M, Arnold A, Binet I, Hunger R, Kempf W, Pascual M, Pelloni F, **Serra A**, Laffitte E.
Rev Med Suisse. 2010 Apr 28;6(246):854-9.
IF 0.121
8. Impact of Mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
Wüthrich RP, Kistler AD, **Serra AL**.
Transplant Proc. 2010 Nov;42:S44-6.
IF 0.952

9. Autosomal-dominante polyzystische Nierenerkrankung: Neue therapeutische Ansätze.
Serra AL, Poster D, Wüthrich RP.
Der Nephrologe. 2010;404-411.
IF 0.000
10. Neue diagnostische Aspekte bei zystischen Nierenerkrankungen.
Kistler D, **Serra AL**.
Der Nephrologe. 2010. 375-383.
IF 0.000
11. Autosomal Dominant Polycystic Kidney Disease: New Treatment Options and How to Test Their Efficacy.
Wüthrich RP, **Serra AL**, Kistler AD.
Kidney Blood Press Res. 2009 Nov 3;32(5):380-387.
IF 1.596
12. Mammalian target of rapamycin and autosomal dominant polycystic kidney disease.
Wüthrich RP, **Serra AL**.
Transplant Proc. 2009 Jul-Aug;41(6 Suppl)
IF 0.952
13. Autosomal dominante polyzystische Nierenerkrankung (ADPKD). Pathogenese, Klinik und neue Therapieansätze.
Serra AL, Wüthrich RP.
Schweiz Med Forum 2009;9(47):854-858.
IF 0.000
14. Autosomal dominant polycystic kidney disease (ADPKD): rapamycin as a new treatment option.
Serra AL, Wüthrich RP.
Praxis (Bern). 2009 Dec 16;98(25):1511-6.
IF 0.059
15. mTOR Inhibitoren bremsen gutartige und bösartige vaskuläre Proliferation am Beispiel von Kaposisarkom und Angiofibrom bei tuberöser Sklerose.
Hofbauer GFL, Marcollo-Pini A, French LE, Wüthrich RP, **Serra AL**.
Derm. Helv. 2009; 1:17-18
IF 0.000
16. Swiss clinical practice guidelines for skin cancer in organ transplant recipients. SGDv working group for organ transplant recipients.
Hofbauer GF, Anliker M, Arnold A, Binet I, Hunger R, Kempf W, Laffitte E, Lapointe AC, Pascual M, Pelloni F, **Serra AL**.
Swiss Med Wkly. 2009 Jul 25;139(29-30):407-15.
IF 1.821
17. Polyzystische Nierenerkrankung: wenn Zysten die Niere zerstören.
Serra AL, Wüthrich RP.
Ärztliche Praxis Urologie 2008; 1:18-21
IF 0.000
18. Use of cinacalcet to control hyperparathyroidism.
Serra AL, Wüthrich RP:
Review of endocrinology, 2008; 2:41-45.
IF 0.000
19. Therapie des persistierenden Hyperparathyreoidismus nach Nierentransplantation.
Serra AL, Wüthrich RP.
Nephrologie im Dialog. 2007; 1:8-12.
IF 0.000
20. Autosomal-dominante polyzystische Nierenerkrankung.
Serra AL, Wüthrich RP.
Der Nephrologe. 2007; 6:459-466
IF 0.000

21. Wie kann die Gefässkalzifikation gestoppt werden?
Serra AL, Wüthrich RP.
CardioVasc. 2006 12-17.
IF 0.000
22. The red urine.
Wüthrich RP, **Serra AL**.
Ther Umsch. 2006; 63:595-600.
IF 0.000
23. Klassifikationen und Therapieoptionen bei chronischer Niereninsuffizienz.
Serra AL, Wüthrich RP.
CardioVasc. 2005 8-13
IF 0.000

C. Angeleitete Dissertationen

Abgeschlossene Dissertationen

1. Herr Wu M. 2010. PhD an der Mathematisch-naturwissenschaftlichen Fakultät der Universität Zürich. Targeting Mammalian Target of Rapamycin (mTOR) Signaling in the Han:SPRD Rat, a Model for Polycystic Kidney Disease.
2. Frau Braun SC. 2008. MD an der Medizinische Fakultät Zürich. Der kalziumsenkende Effekt von Cinacalcet bei nierentransplantierten Patienten mit tertiärem Hyperparathyreoidismus ist durch PTH-abhängige und -unabhängige Mechanismen bedingt.
3. Herr Braun M. 2012. MD an der Medizinische Fakultät Zürich. Ovarian toxicity of Sirolimus.
4. Frau Pavik, I. 2013. PhD an der Mathematisch-naturwissenschaftlichen Fakultät der Universität Zürich. The Role and Regulation of Fibroblast Growth Hormone 23 (FGF23) in Health and Chronic Kidney Disease (CKD).
5. Frau Bühler M. 2013. MD an der Medizinischen Fakultät Zürich. Dermaguard.

Laufenden Dissertationen

1. Frau Liu Y. 2014 geplante Dissertationseinreichung an der Mathematisch-naturwissenschaftlichen Fakultät der Universität Zürich. Dual PI3K/mTOR inhibition prevents sirolimus induced PI3K/Akt and Ras/MAPK pathways up-regulation in polycystic kidney disease.
2. Frau Daniela Spichtig 2015 geplante Dissertationseinreichung an der Mathematisch-naturwissenschaftlichen Fakultät der Universität Zürich. The role of polycystin-1 in bone metabolism.
3. Frau Katja Petzold, 2015 geplante Dissertationseinreichung an der Mathematisch-naturwissenschaftlichen Fakultät der Universität Zürich. Calcium-phosphate metabolism in ADPKD.
4. Frau Leinweber N. 2014 geplante Dissertationseinreichung an der Medizinische Fakultät Zürich. Loss of information of skin health in kidney allograft recipients.
5. Frau Laura Rotar, 2016 geplante Dissertationseinreichung an der Mathematisch-naturwissenschaftlichen Fakultät der Universität Zürich. EuroCYST-multinational academic study in ADPKD.